RecruitingPulmonary Disease, Chronic Obstructive
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
Eligible age
40–80 yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.
Sponsor: GlaxoSmithKline
You may qualify if…
- ✓ Male or eligible female participants
- ✓ Participants with \>=40 to less than or equal to (\<=) 80 years of age.
- ✓ An eosinophilic phenotype with elevated BEC.
- ✓ Moderate to very severe COPD with frequent exacerbations.
- ✓ Participants with elevated COPD assessment test (CAT) score.
- ✓ Current or former cigarette smokers.
- ✓ On triple (Inhaled corticosteroid \[ICS\]+ Long-acting muscarinic antagonist \[LAMA\]+ Long-acting beta-agonist \[LABA\]) or dual inhaled COPD therapy, if ICS is considered not appropriate.
You may not qualify if…
- ✕ Current or prior physician diagnosis of asthma
- ✕ Other clinically significant lung disease.
- ✕ Pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1.
- ✕ Participants with a history of, or plan for lung volume reduction surgery / endobronchial valve procedure.
- ✕ Continuous oxygen therapy (more than 16 hours/ day).
- ✕ Cor pulmonale resulting in right heart failure and severe pulmonary hypertension.
- ✕ A current malignancy or history of malignant neoplasm within the last 5 years (except definitively treated non-melanoma skin cancer or carcinoma in situ of the uterine cervix).
- ✕ Myocardial infarction, unstable angina or stroke within 6 months of screening, unstable arrhythmia.
Where it's recruiting
Source: ClinicalTrials.gov · NCT07780669 · last updated 2026-09-09